002294 Stock Overview
Shenzhen Salubris Pharmaceuticals Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Shenzhen Salubris Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥32.80 |
| 52 Week High | CN¥38.10 |
| 52 Week Low | CN¥23.50 |
| Beta | 0.67 |
| 1 Month Change | -0.76% |
| 3 Month Change | 3.50% |
| 1 Year Change | 7.40% |
| 3 Year Change | 22.25% |
| 5 Year Change | 65.99% |
| Change since IPO | 355.59% |
Recent News & Updates
Is Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) Trading At A 29% Discount?
Dec 18
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Could Signal Some Risk
Nov 29These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely
Nov 11We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings
Sep 02Recent updates
Is Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) Trading At A 29% Discount?
Dec 18Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Could Signal Some Risk
Nov 29These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely
Nov 11We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings
Sep 02What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You
Aug 23Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?
Aug 02Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up
May 22A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)
Apr 17Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?
Feb 28Shareholder Returns
| 002294 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.4% | -1.9% | -1.2% |
| 1Y | 7.4% | -1.8% | 11.8% |
Return vs Industry: 002294 exceeded the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 002294 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 002294 volatility | |
|---|---|
| 002294 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002294 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002294's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 3,517 | Jie Yan | www.salubris.com |
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology, and cardiac rhythm management.
Shenzhen Salubris Pharmaceuticals Co., Ltd. Fundamentals Summary
| 002294 fundamental statistics | |
|---|---|
| Market cap | CN¥36.57b |
| Earnings (TTM) | CN¥610.61m |
| Revenue (TTM) | CN¥3.91b |
59.9x
P/E Ratio9.4x
P/S RatioIs 002294 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002294 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.91b |
| Cost of Revenue | CN¥1.12b |
| Gross Profit | CN¥2.79b |
| Other Expenses | CN¥2.18b |
| Earnings | CN¥610.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 71.37% |
| Net Profit Margin | 15.62% |
| Debt/Equity Ratio | 0.7% |
How did 002294 perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield91%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 20:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen Salubris Pharmaceuticals Co., Ltd. is covered by 23 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| Peng Yan | Changjiang Securities Co. LTD. |
| Liehai Xu | China Merchants Securities Co. Ltd. |